Showing posts with label Drug Study V. Show all posts
Showing posts with label Drug Study V. Show all posts

Valproic Acid Drug Study

Friday, February 20, 2009

In making a Drug Study, the following elements must be present: Generic Name and the Brand name (not all brands, just the brand used by the patient), Action, Indication, Pregnancy Category, Drug Classification, and Contraindication, Adverse Effect, Drug interaction and Nursing Consideration/Intervention…. Most clinical instructors preferred this to be in a long bond paper in printed or handwritten with paper in landscape.

Valproic acid

Pregnancy Category D


Drug class: Antiepileptic agent


Therapeutic actions

Mechanism of action not understood: antiepileptic activity may be related to the metabolism of the inhibitory neurotransmitter, gamma-aminobutyric acid (GABA); divalproex sodium is a compound containing equal proportions of valproic acid and sodium valproate.


Indications

· Sole and adjunctive therapy in simple (petit mal) and complex absence seizures

· Adjunctive therapy with multiple seizure types, including absence seizures

· Treatment of mania (divalproex)

· Prophylaxis of migraine headaches (divalproex-DR tablets)

· Treatment of complex partial seizures as monotherapy or with other antiepilepsy drugs (divalproex, sodium valproate injection)

· Unlabeled uses: sole and adjunctive therapy in atypical absence, myoclonic and grand mal seizures; possibly effective therapy in atonic, elementary partial, and infantile spasm seizures; prophylaxis for recurrent febrile seizures in children


Contraindications

· Contraindicated with hypersensitivity to valproic acid, hepatic disease or significant hepatic dysfunction.

· Use cautiously with children <>


Adverse effects

Sedation, tremor (may be dose-related), emotional upset, depression, psychosis, aggression, hyperactivity, behavioral deterioration, weakness

Transient increases in hair loss, rash, petechiae

Nausea, vomiting, indigestion, diarrhea, abdominal cramps, constipation, anorexia with weight loss, increased appetite with weight gain, life-threatening pancreatitis, hepatic failure

Irregular menses, secondary amenorrhea

Slight elevations in AST, ALT, LDH; increases in serum bilirubin, abnormal changes in other liver function tests, altered bleeding time; thrombocytopenia; bruising; hematoma formation; frank hemorrhage; relative lymphocytosis; hypofibrinogenemia; leukopenia, eosinophilia, anemia, bone marrow suppression


Drug Interactions:

· Increased serum phenobarbital, primidone, ethosuximide, diazepam, zidovudine levels

· Complex interactions with phenytoin; breakthrough seizures have occurred with the combination of valproic acid and phenytoin

· Increased serum levels and toxicity with salicylates, cimetidine, chlorpromazine, erythromycin, felbamate

· Decreased effects with carbamazepine, rifampin, lamotrigine

· Decreased serum levels with charcoal

· Increased sedation with alcohol, other CNS depressants


Nursing considerations

CLINICAL ALERT!

Confusion has occurred between delayed release Depakote and Depakote ER. Dosage is very different and serious adverse effects can occur; use extreme caution.

· Give drug with food if GI upset occurs; substitution of the enteric-coated formulation also may be of benefit; have patient swallow SR tablet whole; do not cut, crush, or chew.

· Reduce dosage, discontinue, or substitute other antiepileptic medication gradually; abrupt discontinuation of all antiepileptic medication may precipitate absence status.

· Arrange for frequent liver function tests; discontinue drug immediately with significant hepatic dysfunction, suspected or apparent; hepatic dysfunction has progressed in spite of drug discontinuation.

· Arrange for patient to have platelet counts, bleeding time determination before therapy, periodically during therapy, and prior to surgery. Monitor patient carefully for clotting defects (bruising, blood tinged toothbrush). Discontinue if there is evidence of hemorrhage, bruising, or disorder of hemostasis.

· Monitor ammonia levels, and discontinue if there is clinically significant elevation in level.

· Monitor serum levels of valproic acid and other antiepileptic drugs given concomitantly, especially during the first few weeks of therapy. Adjust dosage on the basis of these data and clinical response.

· Arrange for counseling for women of childbearing age who wish to become pregnant.

· Discontinue drug at any sign of pancreatitis.

· Evaluate for therapeutic serum levels--usually 50–100 mcg/mL.

Verapamil HCl Drug Study

In making a Drug Study, the following elements must be present: Generic Name and the Brand name (not all brands, just the brand used by the patient), Action, Indication, Pregnancy Category, Drug Classification, and Contraindication, Adverse Effect, Drug interaction and Nursing Consideration/Intervention…. Most clinical instructors preferred this to be in a long bond paper in printed or handwritten with paper in landscape.


Verapamil hydrochloride

Brand Name: Calan, Calan SR, Covera-HS, Isoptin, Isoptin SR, Verelan, Verelan PM,

Pregnancy Category C

Drug classes: Calcium channel-blocker, Antianginal agent, Antiarrhythmic, Antihypertensive

Therapeutic actions

Inhibits the movement of calcium ions across the membranes of cardiac and arterial muscle cells; calcium is involved in the generation of the action potential in specialized automatic and conducting cells in the heart, in arterial smooth muscle, and in excitation-contraction coupling in cardiac muscle cells; inhibition of transmembrane calcium flow results in the depression of impulse formation in specialized cardiac pacemaker cells, slowing of the velocity of conduction of the cardiac impulse, the depression of myocardial contractility, and the dilation of coronary arteries and arterioles and peripheral arterioles; these effects lead to decreased cardiac work, decreased cardiac energy consumption, and in patients with vasospastic (Prinzmetal's) angina, increased delivery of oxygen to myocardial cells.

Indications

· Angina pectoris due to coronary artery spasm (Prinzmetal's variant angina)

· Effort-associated angina

· Chronic stable angina in patients who cannot tolerate or do not respond to beta-adrenergic blockers or nitrates

· Unstable, crescendo, preinfarction angina

· Essential hypertension (sustained-release oral only)

· Treatment of supraventricular tachyarrhythmias (parenteral)

· Temporary control of rapid ventricular rate in atrial flutter or atrial fibrillation (parenteral)

· Unlabeled oral uses: paroxysmal supraventricular tachycardia, migraine headache, nocturnal leg cramps, hypertrophic cardiomyopathy

Contraindications

· Contraindicated with allergy to verapamil; sick sinus syndrome, except with ventricular pacemaker; heart block (second- or third-degree); hypotension; pregnancy; lactation.

· Use cautiously with idiopathic hypertrophic subaortic stenosis, cardiogenic shock, severe CHF, impaired renal or hepatic function, and in patients with atrial flutter or atrial fibrillation and an accessory to bypass tract.

Adverse effects

Dizziness, vertigo, emotional depression, sleepiness, headache, Peripheral edema, hypotension, arrhythmias, bradycardia; AV heart block, Nausea, constipation, Muscle fatigue, diaphoresis, rash

· Increased cardiac depression with beta-adrenergic blocking agents

· Additive effects of verapamil and digoxin to slow AV conduction

· Increased serum levels of digoxin, carbamazepine, prazosin, quinidine

· Increased respiratory depression with atracurium, gallamine, pancuronium, rucuronium, tubocurarine, vecuronium

· Risk of serious cardiac effects with IV beta-adrenergic blocking agents; do not give these drugs within 48 hr before or 24 hr after IV verapamil

· Decreased effects with calcium, rifampin

· Monitor patient carefully (BP, cardiac rhythm, and output) while drug is being titrated to therapeutic dose. Dosage may be increased more rapidly in hospitalized patients under close supervision.

· Ensure that patient swallows SR tablets whole: do not cut, crush, or chew.

· Monitor BP very carefully with concurrent doses of antihypertensives.

· Monitor cardiac rhythm regularly during stabilization of dosage and periodically during long-term therapy.

· Administer sustained-release form in the morning with food to decrease GI upset.

· Protect IV solution from light.

· Monitor patients with renal or hepatic impairment carefully for possible drug accumulation and adverse reactions.

Estradiol Drug Study

In making a Drug Study, the following elements must be present: Generic Name and the Brand name (not all brands, just the brand used by the patient), Action, Indication, Pregnancy Category, Drug Classification, and Contraindication, Adverse Effect, Drug interaction and Nursing Consideration/Intervention…. Most clinical instructors preferred this to be in a long bond paper in printed or handwritten with paper in landscape.

estradiol hemihydrate

Brand Name: Vagifem

Pregnancy Category X

Drug classes: Hormone, Estrogen


Therapeutic actions

Estradiol is the most potent endogenous female sex hormone. Estrogens are important in the development of the female reproductive system and secondary sex characteristics; affect the release of pituitary gonadotropins; cause capillary dilatation, fluid retention, protein anabolism and thin cervical mucus; conserve calcium and phosphorus and encourage bone formation; inhibit ovulation and prevent postpartum breast discomfort. They are responsible for the proliferation of the endometrium; absence or decline of estrogen produces signs and symptoms of menopause on the uterus, vagina, breasts, cervix; relief in androgen-dependent prostatic carcinoma is attributable to competition with androgens for receptor sites, decreasing the influence of androgens.


Indications

· Palliation of moderate to severe vasomotor symptoms, atrophic vaginitis or kraurosis vulvae associated with menopause; prevention of postmenopausal osteoporosis (estradiol oral, transdermal, cream, estradiol valerate)

· Treatment of female hypogonadism, female castration, primary ovarian failure (estradiol oral, transdermal, estradiol cypionate, valerate)

· Palliation of inoperable prostatic cancer (estradiol oral, estradiol valerate)

· Palliation of inoperable, progressing breast cancer (estradiol oral)


Contraindications

· Contraindicated with allergy to estrogens, allergy to tartrazine (in 2-mg oral tablets), breast cancer (with exceptions), estrogen-dependent neoplasm, undiagnosed abnormal genital bleeding, active or past history of thrombophlebitis or thromboembolic disorders (potential serious fetal defects; women of childbearing age should be advised of risks and birth control measures suggested).


Adverse effects

Steepening of the corneal curvature with a resultant change in visual acuity and intolerance to contact lenses, headache, migraine, dizziness, mental depression, chorea, convulsions

Increased blood pressure, thromboembolic and thrombotic disease

Photosensitivity, peripheral edema, chloasma, erythema nodosum or multiforme, hemorrhagic eruption, loss of scalp hair, hirsutism, urticaria, dermatitis

Gallbladder disease (in postmenopausal women), hepatic adenoma, nausea, vomiting, abdominal cramps, bloating, cholestatic jaundice, colitis, acute pancreatitis

Increased risk of postmenopausal endometrial cancer, breakthrough bleeding, change in menstrual flow, dysmenorrhea, premenstrual-like syndrome, amenorrhea, vaginal candidiasis, cystitis-like syndrome, endometrial cystic hyperplasia

Hypercalcemia, decreased glucose tolerance

Pain at injection site, sterile abscess, postinjection flare

Weight changes, reduced carbohydrate tolerance, aggravation of porphyria, edema, changes in libido, breast tenderness

Topical vaginal cream

Systemic absorption may cause uterine bleeding in menopausal women and may cause serious bleeding of remaining endometrial foci in sterilized women with endometriosis.


Drug Interactions:

· Increased therapeutic and toxic effects of corticosteroids

· Decreased serum levels of estradiol with drugs that enhance hepatic metabolism of the drug: barbiturates, phenytoin, rifampin


Nursing considerations

· Arrange for pretreatment and periodic (at least annual) history and physical, which should include BP, breasts, abdomen, pelvic organs, and a Pap smear.

· Caution patient of the risks of estrogen use, the need to prevent pregnancy during treatment, for frequent medical follow-up, and for periodic rests from drug treatment.

· Administer cyclically for short-term only when treating postmenopausal conditions because of the risk of endometrial neoplasm; taper to the lowest effective dose, and provide a drug-free week each month.

· Apply transdermal system to a clean, dry area of skin on the trunk of the body, preferably the abdomen; do not apply to breasts; rotate the site at least 1 wk between applications; avoid the waistline because clothing may rub the system off; apply immediately after opening and compress for about 10 sec to attach.

· Insert vaginal ring as deeply as possible into upper one-third of vagina. Ring will remain in place for 3 months. Then, remove and evaluate need for continued therapy. If a ring falls out during 3 mo, rinse with warm water and reinsert.

· Arrange for the concomitant use of progestin therapy during long-term estrogen therapy; this will mimic normal physiologic cycling and allow for a cyclic uterine bleeding that may decrease the risk of endometrial cancer.

· Administer parenteral preparations by deep IM injection only. Monitor injection sites and rotate with each injection to decrease development of abscesses.